NCT01560260已完成2 期
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 8
- 主要终点
- Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1
研究概览
简要总结
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To determine the response rate to treatment with OSI-906 (linsitinib) 150mg BID in patients with advanced wild-type (WT) gastrointestinal stromal tumor (GIST).
SECONDARY OBJECTIVES:
I. To determine the clinical benefit rate (CBR) (stable disease [SD] >= 9 months, partial response [PR], or complete response [CR]) in patients with advanced WT GIST treated with OSI-906.
II. To determine the response duration, progression free survival (PFS), and overall survival (OS) in patients with advanced WT GIST treated with OSI-906.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed gastrointestinal stromal tumor (GIST) with confirmed genotype of wild-type in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory
- •Patients will be stratified into pediatric and adult cohorts; patients in the pediatric cohort (age at diagnosis =< 18 years OR diagnosis of Carney Triad or Carney-Stratakis Diad (paraganglioma, pulmonary chondroma) must have received at least sunitinib and have had progression on or intolerance to progression on therapy; patients in the adult cohort (age at diagnosis > 18 years AND no diagnosis of diagnosis of Carney Triad or Carney-Stratakis Diad) have had progression on or intolerance to imatinib therapy as documented by treating physician
- •Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2
- •Patients must have measurable disease defined as lesions that can be measured in 2 dimensions by medical imaging techniques such as CT or magnetic resonance imaging (MRI); ascites, pleural fluid, and lesions seen on PET scan only are not considered measurable
- •White blood cells count (WBC) >= 2.0 x 10^9/L (being >= 14 days off growth factors) OR
- •Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (being >= 14 days off growth factors)
- •Platelet count >= 75 x 10^9/L
- •Total bilirubin =< 1.5 times the upper limit of normal for age
- •Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) (serum glutamate pyruvate transaminase [SGPT]/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x the upper limit of normal (ULN) for the reference lab (=< 5 x the ULN for the reference lab in the presence of known hepatic metastasis, adjusted for age)
- •Creatinine clearance > 70 ml/min/1.73m^2 or
- •Serum creatinine < 1.5 x ULN per age and gender
- •QT interval corrected using Frederica formula (QTcF) interval average of < 450 msec at baseline using the Frederica formula (QTcF)
- •No concomitant drugs that prolong the QT corrected (QTc) interval
- •No significant cardiac disease
- •Fasting blood glucose < 150 mg/dL at baseline
- •Hemoglobin A1C (HbA1c) < 7% at screening
- •Patients or their legal representative must be able to read, understand and provide written informed consent to participate in the trial
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of childbearing potential must provide a negative pregnancy test (serum or urine) within 7days prior to registration
- •Patients with diabetes mellitus should have controlled disease on oral medications, defined as: no diabetic ketoacidosis (hyperglycemia, ketonuria, pH < 7.3 and bicarbonate < 15mEq/L) at the time of enrollment or within 30 days prior to enrollment and; no change in oral medications greater than 10% within 30 days prior to enrollment
- •Patient must be able to swallow to participate in the study
- •Signed informed consent
排除标准
- •Time elapsed from previous therapy must be >= 3 weeks except for prior tyrosine kinase inhibitor therapy which can be >= 7 days; patients must be recovered from the effects of any prior surgery, radiotherapy or systemic therapy
- •Patients who are receiving any other investigational agents or other anti-cancer therapies other than those administered in this study during protocol treatment
- •Patients with diabetes mellitus requiring insulin for control of their diabetes
- •Patients with a history of liver cirrhosis
- •Patients with known brain metastases should be excluded from this clinical trial
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to linsitinib (OSI-906)
- •While cytochrome P450 1A2 (CYP1A2) inhibitors/inducers are not specifically excluded, investigators should be aware that linsitinib (OSI 906) exposure may be altered by the concomitant administration of these drugs
- •While cytochrome P450 2C9 (CYP2C9) substrates are not specifically excluded, investigators should be aware that levels of drugs metabolized by CYP2C9 may be increased by the concomitant administration of linsitinib (OSI-906); caution should be used when administering CYP2C9 substrates to patients who are on study drug
- •Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine are prohibited; other less potent CYP1A2 inhibitors/inducers are not excluded
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Prior treatment with another kinase inhibitor targeting insulin-like growth factor 1 receptor (IGF-1R) pathway, including monoclonal antibodies targeting IGF-1R
- •Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with linsitinib (OSI-906)
- •Fertile men and women of childbearing potential not employing an effective method of birth control throughout the trial and for 3 months after last study drug administration in both sexes; women of childbearing potential must have a negative pregnancy test (serum or urine) within the 7 days prior to study drug administration
- •NOTE: Women of childbearing potential include both pre-menopausal women and women within the first 2 years of the onset of menopause
- •NOTE: Effective methods of birth control includes: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, abstinence; oral contraceptive pills (OCPs) alone are not considered an effective method
- •Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
- •Use of drugs that have a known risk of causing Torsades de Pointes (TdP) are prohibited within 14 days prior to initiation of linsitinib (OSI-906)
- •Patients with a history of solid organ transplant are ineligible
研究组 & 干预措施
Treatment (linsitinib)
Experimental
Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (linsitinib)
Experimental
Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Linsitinib (Drug)
Treatment (linsitinib)
Experimental
Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Pharmacological Study (Other)
结局指标
主要结局
Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1
时间窗: At 6 months
Determine the response rate, Complete Response (CR) or Partial Response (PR), to treatment with linsitinib (OSI-906) in patients with advanced wild-type (WT) gastrointestional stromal tumor (GIST) as determined by RECIST 1.1.
次要结局
- Patterns of Protein Expression in Serum and Tumor Tissues as Predictors of Response and PFS(Up to 37 weeks)
- Clinical Benefit Rate Defined as Stable Disease (SD) >= 9 Months, Partial Response (PR) or Complete Response (CR)(Up to 2 years)
- Overall Survival (OS)(Estimates at 9 months)
- Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response.(Up to 37 weeks)
- Response Duration(Up to 37 weeks)
- Tolerability and Adverse Event Profile of Linsitinib(Up to 37 weeks)
- Number of Participants With Metabolic Response to Linsitinib Using FDG-PET.(Up to 37 weeks)
- Progression Free Survival (PFS)(Time from date of enrollment to time of progression or death due to any cause, estimates at 9 months)
- Failure-free Survival(Up to 37 weeks)
- Changes in Tumor Metabolism by FDG-PET Qualitatively and Semi-quantitatively With Standard Uptake Value (SUV)(Baseline and 8 weeks)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Graves OrbitopathyEndocrine System DiseasesEye DiseasesThyroid Associated OphthalmopathyGraves OphthalmopathyThyroid DiseasesOrbital DiseasesIGF1RHashimotoThyroid Eye DiseaseProptosisExophthalmosNCT05276063Sling Therapeutics, Inc.90
已完成
2 期
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal TumorGastrointestinal Stromal TumorsNCT01396148Pfizer6
已完成
2 期
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasPlexiform NeurofibromaNeurofibromatosis Type 1NCT03231306University of Alabama at Birmingham45
已完成
2 期
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial SarcomaPleuropulmonary BlastomaRecurrent Malignant Peripheral Nerve Sheath TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRecurrent Synovial SarcomaWilms TumorNCT02452554Children's Oncology Group62
已完成
2 期
Phase II trial of Linsitinib (anti-IGF-1R/IR) in patients with relapsed and/or refractory Ewing SarcomaEwing sarcoma10028389NL-OMON43946niversity of Oxford7